| Autor: |
Tuyls S; Pulmonology Department, Sint Augustinus Ziekenhuis GZA, Antwerpen and UZ Leuven, Leuven, Belgium., Van Der Brempt X; Pulmonology Department and Allergopôle, Clinique Saint-Luc, Bouge, Belgium., Faber M; Allergology and Immunology Department, World Allergy Organization (WAO) Center of Excellence, Universitaire Ziekenhuizen Antwerpen and Universiteit Antwerpen, Antwerpen, Belgium., Gadisseur R; Clinical Biology Department, CHU Liège and Université de Liège, Liège, Belgium., Dezfoulian B; Dermatology Department, CHU Liège and Université de Liège, Liège, Belgium., Schrijvers R; KU Leuven Department of Microbiology, Immunology and Transplantation, Allergy and Clinical Immunology Research Group, KU Leuven, Leuven, Belgium., Froidure A; Pulmonology Department, WAO Center of Excellence, Cliniques Universitaires Saint-Luc, Bruxelles, Belgium.; Institut de Recherche Expérimentale et Clinique, Université Catholique de Louvain, Bruxelles, Belgium. |
| Abstrakt: |
Vaccination against COVID-19 constitutes a huge hope and a major challenge. For the first time in modern history, a global vaccination campaign has started worldwide in a short period of time and with products that were recently developed. Consequently, legitimate concerns regarding the safety and tolerability of COVID-19 vaccines arise.In line with international allergy societies, the Belgian Society for Allergy and Clinical Immunology (BelSACI) provides this statement to guide health care providers (general practitioners, specialists including allergists) and stakeholders.In this statement, we first review current evidence on allergic reactions to vaccines and the potential risk factors that have been identified.Second, we provide a risk stratification method that may be used as a worksheet during the vaccination campaign.Finally, we discuss the management of suspected or confirmed allergic reactions following vaccination. |
